Nordea Bank Finland Plc issues Equity-Linked Notes – Medicinalvirksomheder 2018


Copenhagen, 2014-03-07 10:09 CET (GLOBE NEWSWIRE) --  

 

Nordea Bank Finland Plc (the "Issuer") issues a series (A419) of Equity-Linked Notes due 12 June 2018, Medicinalvirksomheder 2018, denominated in Danish Kroner ("DKK") with ISIN Code DK0030334651 and Common Code 104345140 (the "Notes").

The Notes are to be issued on 3 April 2014 and will be redeemed on 12 June 2018 in accordance with "Locally capped Basket" structure. The return of the Notes depends on the performance of a basket of containing the shares of seven (7) pharmaceutical companies (the "Reference Assets") where the return of each Reference Assets is subject to a pre-determined maximum percentage value ("Maximum Performance") for the purpose of determining the overall performance of the Basket. Maximum Performance is indicatively 65 pct.

Full information on the Issuer and the offer of the Notes is only available on the basis of the combination of the Final Terms of the Notes dated 7 March 2014 and the Base Prospectus as so supplemented.

The offer period for the Notes will take place during the period from 10 March 2014, 9:00 CET until 28 March 2014, 16.00 CET. The Aggregate Nominal Amount of the Notes and the final Maximum Performance will be determined after the subscription period and will be announced in a Final Terms Confirmation Announcement through NASDAQ OMX Copenhagen A/S.

The Issuer reserves its rights to cancel the offer if the aggregate principal amount of Notes subscribed on or before the issue date is less than DKK 50,000,000, if Maximum Performance cannot be set to at least 55.00 per cent, or if any event of an economic, financial or political nature occurs and which may jeopardise a successful offer, as determined by the Issuer. The Issuer may also replace any of the Reference Assets at any time on or prior to Issue Date by a comparable type of underlying Reference Asset. The Notes will be issued and registered with VP Securities A/S on 3 April 2014 and be admitted to trading and official listing on NASDAQ OMX Copenhagen A/S with the first day of trading on the same day.

We refer to the published Final Terms of the Notes.

Questions regarding the Notes may be directed to Peter Kijne, Nordea Markets, telephone 33 33 53 39.

 

 


Attachments

Press release NBF Medicinalvirksomheder 2018.pdf FT NBF Medicinalvirksomheder 2018_exe.pdf